An observational study on dapagliflozin as an add-on therapy in type-2 diabetes mellitus patients in a tertiary care teaching hospital

Authors

  • Venugopal Reddy M. Department of Pharmacology, Kurnool Medical College, Kurnool, Andhra Pradesh, India
  • Christina Sahayaraj Department of Pharmacology, Kurnool Medical College, Kurnool, Andhra Pradesh, India
  • Shaik Haseena Begum Department of Pharmacology, Kurnool Medical College, Kurnool, Andhra Pradesh, India
  • Sharon Sonia S. Department of Pharmacology, Government Medical College, Anantapur, Andhra Pradesh, India
  • Vijayabhaskar Reddy Y. Department of Pharmacology, Kurnool Medical College, Kurnool, Andhra Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20230393

Keywords:

Dapagliflozin, SGLT-2 Inhibitor, Type-2DM, FBG, HbA1c

Abstract

Background: Diabetes mellitus is one of the prevalent morbid conditions all over the world and no exception for India. Day by day, increase in its prevalence is attributed to lifestyle derangements. To treat this condition many drugs and treatment modalities are developed. Dapagliflozin is an oral antidiabetic drug which acts by sodium-glucose cotransport-2 (SGLT-2) inhibition. Its effectiveness seen in type-2 diabetes mellitus makes it an option for Add-On therapy.

Methods: This study is a retrospective observational study conducted at tertiary care hospital, GGH, Kurnool. The study proposal has been reviewed and approved by institutional ethics committee. All adult diabetic patients who were prescribed Dapagliflozin during the period of January 2021 to February 2022, total 45 were included in the study. FBG, HbA1c collected through hospital records from General Medicine and Endocrinology. Patients who stopped drug before 3 months period were excluded.

Results: Administration of dapagliflozin as an add-on therapy was found 26.63% decrease in base line mean FBG 184 mg/dl to 135 mg/dl after 3mnoths which is significant (p=0.001). Mean HbA1c significantly reduced by 0.96 percentage point after 3 months (p=0.001). Dapagliflozin effectively reduced the FBG and HbA1c when used in combination with other OHAs or insulin within 3 months.

Conclusions: Dapagliflozin as an add-on therapy significantly reduced the HbA1c level and fasting blood glucose of Type-2DM patients, in a 3-month treatment period. Due to the frequency of Genitourinary tract infections, caution is indicated while treating the patients.

References

Patel R, Keyes D. Lifestyle modification for diabetes and heart disease prevention. Stat Pearls. Treasure Island (FL): StatPearls Publishing; 2022.

Sachdeva M, Dhingra S, Parle M. Dapagliflozin: a new adjunct in the treatment of Type 2 diabetes mellitus. Int J Basic Clin Pharmacol. 2017;3(4):741-7.

Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136-42.

DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5-14.

Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014;53(1):17-27.

Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm. Endocr Pract. 2020;26(1):107-39.

Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32(2):S151-6.

Albarrán OG, Ampudia-Blasco FJ. Dapagliflozina, el primer inhibidor SGLT 2 en el tratamiento de la diabetes tipo 2. Med Clin. 2013;141(2):36-43.

Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015;14:142.

Jeon HJ, Ku EJ, Oh TK. Dapagliflozin improves blood glucose in diabetes on triple oral hypoglycemic agents having inadequate glucose control. Diabetes Res Clin Pract. 2018;142:188-194.

Al AdAwi RM, Jassim Z, Elgaily D, Abdelaziz H, Sree B, Mohamed Ibrahim MI. Assessment of dapagliflozin effectiveness as add-on therapy for the treatment of type 2 diabetes mellitus in a Qatari Population. Sci Rep. 2019;9(1):6864.

Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928-38.

Ott C, Jumar A, Striepe K, Friedrich S, Karg MV, Bramlage P, Schmieder RE. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol. 2017;16(1):26.

Patel DK, Strong J. The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit. Diabetes Ther. 2019;10(5):1771-92.

Takata T, Isomoto H. Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control. Int J Mol Sci. 2021;22(9):4374

Downloads

Published

2023-02-22

How to Cite

Reddy M. , V., Sahayaraj, C., Haseena Begum, S., Sonia S. , S., & Reddy Y. , V. (2023). An observational study on dapagliflozin as an add-on therapy in type-2 diabetes mellitus patients in a tertiary care teaching hospital. International Journal of Basic & Clinical Pharmacology, 12(2), 232–235. https://doi.org/10.18203/2319-2003.ijbcp20230393

Issue

Section

Original Research Articles